on September 27, 2007
Published online before print September 27, 2007, doi: 10.1161/STROKEAHA.107.491472
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 17, 2007
From the Department of Neurology, University of Cincinnati, Ohio. * To whom correspondence should be addressed. E-mail: Daniel.woo{at}uc.edu.
Background and Purpose—Selective serotonin reuptake inhibitors (SSRI) are widely prescribed. Several reports have observed an increased bleeding risk associated with SSRI use, which is hypothesized to be secondary to their antiplatelet effect. Methods—We tested the hypothesis that SSRIs increase the risk for or potentiate the risk of hemorrhagic stroke associated with antiplatelets and anticoagulants. Results—In multivariate analysis, we found no increased risk associated with SSRI use for intracerebral hemorrhage (odds ratio=1.1, 95% CI: 0.7 to 1.8; P=0.63) or subarachnoid hemorrhage (odds ratio=0.6, 95% CI: 0.4 to 1.0; P=0.054). In addition, potentiation of risk with warfarin or antiplatelets was not observed. Conclusions—Further studies with larger populations would be needed to exclude a small increase in intracranial hemorrhage risk with SSRI use.
Accepted on April 27, 2007
Selective Serotonin Reuptake Inhibitors and Risk of Hemorrhagic Stroke
Jordan Kharofa BS;
Key words: hemorrhage • SSRI • stroke
This article has been cited by other articles:
 |
|
 |
|
  Y. Chen, J. J Guo, H. Li, L. Wulsin, and N. C Patel Risk of Cerebrovascular Events Associated with Antidepressant Use in Patients with Depression: A Population-Based, Nested Case-Control Study Ann. Pharmacother., February 1, 2008; 42(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|